* Sees $4.2 mln charge in 2010 H1
* Expects to save about $15.6 mln annually
* Shares down 4 pct
March 5 XenoPort Inc XNPT.O said it would cut
its workforce by about 50 percent to focus on the development
of its product candidates, and would take a related charge of
$4.2 million in the first half of 2010.
As of Dec. 31, 2009, XenoPort had 219 full-time employees,
according to a regulatory filing.
The company said it would save about $15.6 million yearly
from the restructuring.
XenoPort will focus on the approval process of its restless
leg syndrome drug, Horizant, complete its ongoing mid-stage
trial of arbaclofen placarbil in gastroesophageal reflux
disease and start a mid-stage trial of XP21279 for Parkinson's
Last month, the U.S. Food and Drug Administration issued a
complete response letter for Horizant -- a long-lasting version
of the drug gabapentin that is approved for refractory epilepsy
-- citing a potential link to cancer found in rats.
Shares of the company fell 4 percent to $7.56 Friday
afternoon on Nasdaq.
(Reporting by Anand Basu in Bangalore; Editing by Ratul Ray